PMC:7307149 / 4209-4619
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T25","span":{"begin":59,"end":72},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma9825"}],"text":"Other similarities (20–22), including genomic (23, 24) and immune system response (25–33) similarities, between SARS-CoV-2 and other coronaviruses (34), especially SARS-CoV and MERS-CoV, are topics of ongoing active research, results of which may inform an understanding of the severity of infection (35) and improve the ongoing work of immune landscape profiling (36–40) and vaccine discovery (28, 37, 41–48)."}
LitCovid-PD-UBERON
{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":59,"end":72},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"Other similarities (20–22), including genomic (23, 24) and immune system response (25–33) similarities, between SARS-CoV-2 and other coronaviruses (34), especially SARS-CoV and MERS-CoV, are topics of ongoing active research, results of which may inform an understanding of the severity of infection (35) and improve the ongoing work of immune landscape profiling (36–40) and vaccine discovery (28, 37, 41–48)."}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T37","span":{"begin":112,"end":120},"obj":"Disease"},{"id":"T38","span":{"begin":164,"end":172},"obj":"Disease"},{"id":"T39","span":{"begin":290,"end":299},"obj":"Disease"}],"attributes":[{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Other similarities (20–22), including genomic (23, 24) and immune system response (25–33) similarities, between SARS-CoV-2 and other coronaviruses (34), especially SARS-CoV and MERS-CoV, are topics of ongoing active research, results of which may inform an understanding of the severity of infection (35) and improve the ongoing work of immune landscape profiling (36–40) and vaccine discovery (28, 37, 41–48)."}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T43","span":{"begin":23,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T44","span":{"begin":59,"end":72},"obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"T45","span":{"begin":148,"end":150},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T46","span":{"begin":209,"end":215},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T47","span":{"begin":301,"end":303},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T48","span":{"begin":365,"end":367},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T49","span":{"begin":403,"end":405},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T50","span":{"begin":406,"end":408},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"}],"text":"Other similarities (20–22), including genomic (23, 24) and immune system response (25–33) similarities, between SARS-CoV-2 and other coronaviruses (34), especially SARS-CoV and MERS-CoV, are topics of ongoing active research, results of which may inform an understanding of the severity of infection (35) and improve the ongoing work of immune landscape profiling (36–40) and vaccine discovery (28, 37, 41–48)."}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"103","span":{"begin":164,"end":172},"obj":"Species"},{"id":"104","span":{"begin":177,"end":185},"obj":"Species"}],"attributes":[{"id":"A103","pred":"tao:has_database_id","subj":"103","obj":"Tax:694009"},{"id":"A104","pred":"tao:has_database_id","subj":"104","obj":"Tax:1335626"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Other similarities (20–22), including genomic (23, 24) and immune system response (25–33) similarities, between SARS-CoV-2 and other coronaviruses (34), especially SARS-CoV and MERS-CoV, are topics of ongoing active research, results of which may inform an understanding of the severity of infection (35) and improve the ongoing work of immune landscape profiling (36–40) and vaccine discovery (28, 37, 41–48)."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T34","span":{"begin":0,"end":410},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Other similarities (20–22), including genomic (23, 24) and immune system response (25–33) similarities, between SARS-CoV-2 and other coronaviruses (34), especially SARS-CoV and MERS-CoV, are topics of ongoing active research, results of which may inform an understanding of the severity of infection (35) and improve the ongoing work of immune landscape profiling (36–40) and vaccine discovery (28, 37, 41–48)."}
2_test
{"project":"2_test","denotations":[{"id":"32303592-32143502-65501623","span":{"begin":20,"end":22},"obj":"32143502"},{"id":"32303592-32027036-65501624","span":{"begin":47,"end":49},"obj":"32027036"},{"id":"32303592-32007145-65501625","span":{"begin":51,"end":53},"obj":"32007145"},{"id":"32303592-32105090-65501626","span":{"begin":83,"end":85},"obj":"32105090"},{"id":"32303592-32092539-65501627","span":{"begin":301,"end":303},"obj":"32092539"},{"id":"32303592-32106567-65501628","span":{"begin":395,"end":397},"obj":"32106567"}],"text":"Other similarities (20–22), including genomic (23, 24) and immune system response (25–33) similarities, between SARS-CoV-2 and other coronaviruses (34), especially SARS-CoV and MERS-CoV, are topics of ongoing active research, results of which may inform an understanding of the severity of infection (35) and improve the ongoing work of immune landscape profiling (36–40) and vaccine discovery (28, 37, 41–48)."}